- CEO
- Li Li
- Full Time Employees
- 42,817
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- No. 188, N. Twr of Aier Ophthalmology Bl Changsha HU China 410015
- IPO Date
- Nov 2, 2009
- Business
- Aier Eye Hospital Group Co., Ltd. (300015.SZ) operates as China's largest provider of ophthalmology chain medical services, principally engaged in the diagnosis and treatment of various ophthalmic diseases, surgical services, and medical optometry; core offerings encompass refractive surgery including myopia correction, cataract surgery, anterior segment surgery such as glaucoma and corneal treatments, posterior segment surgery for fundus diseases, pediatric ophthalmology, optometry services, eyeglasses, and specialized treatments for lacrimal pathology, ocular surface conditions, and eye contouring aesthetics. Founded in 2002 or 2003 and headquartered in Changsha, Hunan province, the company manages an extensive global network of over 900 eye hospitals, centers, and clinics, including approximately 800 in mainland China, 8-9 in Hong Kong, 1 in the United States, more than 100 in Europe, and 14-18 in Southeast Asia, serving patients across Asia, Europe, and North America through subsidiaries such as Clínica Baviera S.A. (listed in Spain as CBAV.MC), ISEC Healthcare Ltd. (listed in Singapore as 40T), MING WANG Eye Center, and Hong Kong Asia Medical. In recent developments, Aier has pursued aggressive expansion via acquisitions, including in July 2024 the purchase of equity stakes in 35 mainland China institutions such as Humen Aier and Yuncheng Aier for CNY 898 million and in May 2024 stakes in 52 others including Chongqing Eye Optometry for CNY 1.344 billion; through its European arm Clínica Baviera, it acquired the UK's Optimax Group (Eye Hospitals Group) in 2024 for approximately €22.75 million to enter the UK market; and in October 2025, it invested in Sichuan Cunde Therapeutics Co., Ltd. as part of a Series A round, alongside additional deals like a 70% stake in Xiangshan Aier Eye Hospital in December 2023 and stakes in Tongren Aier Renai Eye Hospital in August 2025. These moves, which added over 149 subsidiaries to its consolidation scope by end-2024, bolster its domestic dominance and international footprint amid a strategy emphasizing innovation-driven growth and global ophthalmology leadership.